GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Panacea Life Sciences Holdings Inc (OTCPK:PLSH) » Definitions » EV-to-EBIT

Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) EV-to-EBIT : -3.99 (As of May. 16, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Panacea Life Sciences Holdings EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Panacea Life Sciences Holdings's Enterprise Value is $24.18 Mil. Panacea Life Sciences Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.06 Mil. Therefore, Panacea Life Sciences Holdings's EV-to-EBIT for today is -3.99.

The historical rank and industry rank for Panacea Life Sciences Holdings's EV-to-EBIT or its related term are showing as below:

PLSH' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.33   Med: -3.6   Max: -1.89
Current: -3.99

During the past 4 years, the highest EV-to-EBIT of Panacea Life Sciences Holdings was -1.89. The lowest was -4.33. And the median was -3.60.

PLSH's EV-to-EBIT is ranked worse than
100% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.59 vs PLSH: -3.99

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Panacea Life Sciences Holdings's Enterprise Value for the quarter that ended in Mar. 2024 was $25.36 Mil. Panacea Life Sciences Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.06 Mil. Panacea Life Sciences Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -23.91%.


Panacea Life Sciences Holdings EV-to-EBIT Historical Data

The historical data trend for Panacea Life Sciences Holdings's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Life Sciences Holdings EV-to-EBIT Chart

Panacea Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -2.67 -3.74

Panacea Life Sciences Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.76 -4.23 -4.03 -3.74 -4.18

Competitive Comparison of Panacea Life Sciences Holdings's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacea Life Sciences Holdings's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Panacea Life Sciences Holdings's EV-to-EBIT falls into.



Panacea Life Sciences Holdings EV-to-EBIT Calculation

Panacea Life Sciences Holdings's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=24.183/-6.064
=-3.99

Panacea Life Sciences Holdings's current Enterprise Value is $24.18 Mil.
Panacea Life Sciences Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panacea Life Sciences Holdings  (OTCPK:PLSH) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Panacea Life Sciences Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-6.064/25.36114401
=-23.91 %

Panacea Life Sciences Holdings's Enterprise Value for the quarter that ended in Mar. 2024 was $25.36 Mil.
Panacea Life Sciences Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panacea Life Sciences Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Panacea Life Sciences Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) Business Description

Traded in Other Exchanges
N/A
Address
5910 S University Boulevard, C18-193, Greenwood Village, CO, USA, 80121
Panacea Life Sciences Holdings Inc is a cannabinoid nutraceutical manufacturer and research company that produces natural pharmaceutical alternatives for consumers and pets. It manufactures and sells soft gels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals.
Executives
Leslie Buttorff director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER 16194 W 45TH DRIVE, GOLDEN CO 80403
Janice Nerger director 5910 S UNIVERSITY BLVD., C18-193, GREENWOOD VILLAGE CO 80121
Nathan Joel Berman officer: CONTROLLER & PRIN ACTNG OFCR 16194 W 45TH DRIVE, GOLDEN CO 80403
22nd Century Group, Inc. 10 percent owner 8560 MAIN STREET, SUITE 4, WILLIAMSVILLE NY 14221
Harvey J Kesner 10 percent owner 65 E. 55TH STREET, NEW YORK NY 10022
Lawrence Wert director 170 NUTTALL RD, RIVERSIDE IL 60546
Chesne Derek Du officer: Chief Growth Officer 80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Alvaro Daniel Alberttis director 80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Vladislav Yampolsky director, 10 percent owner 332 PLAZA REAL, BOCA RATON FL 33432
Steven A Schwartz director 332 PLAZA REAL, BOCA RATON FL 33432
Andrew L. Johnson officer: Chief Strategy Officer 80 NE 4TH AVE. SUITE 28, DELRAY BEACH FL 33483
Emiliano Angel Aloi officer: President 510 SUNSHINE DRIVE, DELRAY BEACH FL 33444
Jonathan Gilbert director, officer: Executive Chairman 36 SYCAMORE LANE, ROSALYN HEIGHTS NY 11577
John C Price director 4721 IRONTON STREET, BUILDING A, DENVER CO 80239
Kevin James Esval director NEURO HITECH INC, ONE PENN PLAZA STE 1503, NEW YORK NY 10019

Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) Headlines

From GuruFocus

Panacea Announces Letter of Intent to Acquire N7 Enterprises, Inc.

By Stock market mentor Stock market mentor 01-23-2023